<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>218</ContextCount>
  <ElementCount>271</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business</Role>
      <ShortName>Note 1 - Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations</Role>
      <ShortName>Note 3 - Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements</Role>
      <ShortName>Note 4 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories</Role>
      <ShortName>Note 5 - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-</Role>
      <ShortName>Note 6 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill</Role>
      <ShortName>Note 7 - Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases</Role>
      <ShortName>Note 8 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities</Role>
      <ShortName>Note 9 - Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies</Role>
      <ShortName>Note 10 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Revenue and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information</Role>
      <ShortName>Note 11 - Revenue and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan</Role>
      <ShortName>Note 12 - Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes</Role>
      <ShortName>Note 13 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Earnings Per Share ("EPS")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps</Role>
      <ShortName>Note 14 - Earnings Per Share ("EPS")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables</Role>
      <ShortName>Note 3 - Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 4 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables</Role>
      <ShortName>Note 4 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 5 - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables</Role>
      <ShortName>Note 5 - Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 6 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables</Role>
      <ShortName>Note 6 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 7 - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables</Role>
      <ShortName>Note 7 - Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 8 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables</Role>
      <ShortName>Note 8 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables</Role>
      <ShortName>Note 9 - Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 11 - Revenue and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables</Role>
      <ShortName>Note 11 - Revenue and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 12 - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables</Role>
      <ShortName>Note 12 - Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables</Role>
      <ShortName>Note 14 - Earnings Per Share ("EPS") (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 3 - Business Combinations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual</Role>
      <ShortName>Note 3 - Business Combinations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details</Role>
      <ShortName>Note 3 - Business Combinations - Consideration Transferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details</Role>
      <ShortName>Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details</Role>
      <ShortName>Note 3 - Business Combinations - Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details</Role>
      <ShortName>Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details</Role>
      <ShortName>Note 4 - Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 5 - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual</Role>
      <ShortName>Note 5 - Inventories (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details</Role>
      <ShortName>Note 5 - Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 6 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details</Role>
      <ShortName>Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 8 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual</Role>
      <ShortName>Note 8 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 8 - Leases - Future Minimum Rental Payments for Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details</Role>
      <ShortName>Note 8 - Leases - Future Minimum Rental Payments for Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 10 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 11 - Revenue and Geographic Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual</Role>
      <ShortName>Note 11 - Revenue and Geographic Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 11 - Revenue and Geographic Information - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details</Role>
      <ShortName>Note 11 - Revenue and Geographic Information - Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details</Role>
      <ShortName>Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 12 - Equity Incentive Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual</Role>
      <ShortName>Note 12 - Equity Incentive Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details</Role>
      <ShortName>Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 12 - Equity Incentive Plan - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details</Role>
      <ShortName>Note 12 - Equity Incentive Plan - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details</Role>
      <ShortName>Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details</Role>
      <ShortName>Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 12 - Equity Incentive Plan - Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details</Role>
      <ShortName>Note 12 - Equity Incentive Plan - Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 13 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual</Role>
      <ShortName>Note 13 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual</Role>
      <ShortName>Note 14 - Earnings Per Share ("EPS") (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="anik20220930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details</Role>
      <ShortName>Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 32 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DeferredTaxAssetsValuationAllowance, us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProductWarrantyAccrual, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod -  anik20220930_10q.htm 8, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="anik20220930_10q.htm">anik20220930_10q.htm</File>
    <File>anik-20220930.xsd</File>
    <File>anik-20220930_cal.xml</File>
    <File>anik-20220930_def.xml</File>
    <File>anik-20220930_lab.xml</File>
    <File>anik-20220930_pre.xml</File>
    <File>ex_440237.htm</File>
    <File>ex_440238.htm</File>
    <File>ex_440239.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="718">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
